Clinical trials: Stage III Renal Cell Cancer AJCC v8
Kidney Cancer
DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE
RATIONALE: Studying samples of blood and/or tissue in the laboratory from patients with kidney cancer receiving sorafenib may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00900536
- Testing
- mutation analysis, polymorphism analysis, protein expression analysis
- Where
- United Kingdom
- Sponsor
- Medical Research Council
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
This phase II trial studies the side effects of atezolizumab with or without eribulin mesylate and how well they work in treating patients with urothelial cancer that has come back (recurrent), spread to nearby tissues or lymph…
- Conditions
- Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma
- Trial name
- NCT03237780
- Testing
- Atezolizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 21 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer, Stage III Renal Cell Cancer AJCC v8
Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
This phase II trial studies how well lenvatinib and pembrolizumab before surgery work in treating patients with kidney cancer that has spread from its original site of growth to nearby tissues or lymph nodes but has not spread to…
- Conditions
- Kidney Cancer, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Trial name
- NCT04393350
- Testing
- Lenvatinib, Lenvatinib Mesylate, Pembrolizumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Emory University
Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
This phase I trial tests the safety, side effects, and best dose of camu camu when used in combination with nivolumab and ipilimumab in treating patients with kidney cancer that has spread to other places in the body.
- Conditions
- Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Trial name
- NCT06049576
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- City of Hope Medical Center
Advanced Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer
This phase I trial studies how well CBM588 works when given together with nivolumab and ipilimumab in treating patients with kidney cancer that is stage IV or has spread to other places in the body (advanced).
- Conditions
- Advanced Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
- Trial name
- NCT03829111
- Testing
- Clostridium butyricum CBM 588 Probiotic Strain, Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
This phase II trial compares the safety and effectiveness of 89Zr-DFO-GmAb positron emission tomography (PET)/computed tomography (CT) compared to contrast-enhanced CT after surgery in detecting clear cell renal cell cancer that…
- Conditions
- Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer
- Trial name
- NCT06447103
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Kidney Cancer
Gene Expression in Normal Tissue and Tumor Tissue From Patients Who Have Undergone Surgery For Kidney Cancer
RATIONALE: Studying the genes and proteins expressed in tissue samples from patients with cancer may help doctors identify biomarkers related to cancer.
- Trial name
- NCT00899860
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Wake Forest University Health Sciences
Kidney Cancer
Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
RATIONALE: Gefitinib may stop the growth of kidney cancer by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00467077
- Testing
- PEG-interferon alfa-2b, gefitinib
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- California Cancer Consortium
Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
This phase IV trial is evaluating whether morning versus afternoon administration of standard of care immunotherapy impacts its effectiveness in treating patients with solid tumors that may have spread from where it first started…
- Conditions
- Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Lung Non-Small Cell Carcinoma
- Trial name
- NCT07405086
- Testing
- Biospecimen Collection, Immune Checkpoint Inhibitor
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- OHSU Knight Cancer Institute
Kidney Cancer
Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer
RATIONALE: Sunitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00541008
- Testing
- sunitinib malate
- Where
- 22 sites in France
- Volunteers
- 92 people
- Sponsor
- UNICANCER
Kidney Cancer
Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00849186
- Testing
- sunitinib malate, neoadjuvant therapy, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Kidney Cancer
Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00496756
- Testing
- Sorafenib
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Nebraska
Kidney Medullary Carcinoma, Loss of INI 1 Protein Expression
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
This phase II trial studies how well nivolumab and ipilimumab work in treating patients with kidney cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the…
- Conditions
- Kidney Medullary Carcinoma, Loss of INI 1 Protein Expression, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Trial name
- NCT03274258
- Testing
- Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
This phase II trial studies how well axitinib and nivolumab work in treating patients with TFE/translocation renal cell carcinoma that cannot be removed by surgery (unresectable) or has spread to other places in the body…
- Conditions
- Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, TFE3-Rearranged Renal Cell Carcinoma
- Trial name
- NCT03595124
- Testing
- Axitinib, Nivolumab
- Where
- 267 sites in United States, Puerto Rico
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
This phase I trial tests the safety and effectiveness of nivolumab and ipilimumab with and without EXL01 for the treatment of renal cell cancer that has spread from where it first started (primary site) to other places in the…
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma
- Trial name
- NCT07128680
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- City of Hope Medical Center
Clear Cell Papillary Renal Neoplasm, Collecting Duct Carcinoma
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
This phase II trial investigates how well pamiparib and temozolomide work in treating patients with hereditary leiomyomatosis and renal cell (kidney) cancer.
- Conditions
- Clear Cell Papillary Renal Neoplasm, Collecting Duct Carcinoma, Hereditary Leiomyomatosis and Renal Cell Carcinoma, Hereditary Papillary Renal Cell Carcinoma
- Trial name
- NCT04603365
- Testing
- Pamiparib, Temozolomide
- Sponsor
- Jonsson Comprehensive Cancer Center
Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma
Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer
This phase I/II trial studies the side effects and best dose of mercaptopurine, and to see how well it works in treating patients with hereditary leiomyomatosis and renal cell carcinoma (HLRCC).
- Conditions
- Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma, Hereditary Leiomyomatosis and Renal Cell Carcinoma, Metastatic Kidney Carcinoma
- Trial name
- NCT07716735
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Kidney Cancer
Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who have unresectable…
- Trial name
- NCT00016939
- Testing
- alvocidib
- Where
- 101 sites in United States
- Sponsor
- SWOG Cancer Research Network
Kidney Cancer
Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and irinotecan, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00089102
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Medical University of South Carolina
Kidney Cancer
Vaccine Therapy in Treating Patients With Stage III or Stage IV Kidney Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV kidney cancer.
- Trial name
- NCT00005816
- Testing
- therapeutic autologous dendritic cells, conventional surgery
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Duke University